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Introduction: Tenecteplase can be a more effective and convenient alternative in treatment
of prosthetic valve thrombosis (PVT).
Case: We hereby present a case of the use of Tenecteplase for recurrence of mitral valve
thrombosis in a patient who was brought as an emergency with breathing difﬁculty at rest. A
single intravenous bolus of Tenecteplase relieved her symptoms dramatically within a few
hours. This is in contradistinction to her earlier similar presentation with valve thrombosis a
year back, when both streptokinase and urokinase had not worked.
Conclusion: The use of Tenecteplase in PVT is reasonable, but needs more documentation.
The therapeutic response was remarkable in our case. It is also better suited for recurrence of
valve thrombosis as streptokinase cannot be used for a second time.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Prosthetic valve thrombosis (PVT) is considered a life threat-
ening complication following a native cardiac valve replace-
ment. Thrombolytics are indicated for left sided PVT in
patients in New York Heart Association (NYHA) Class I
and II. Although streptokinase and urokinase are labeled for
such use, they both have limitations as the former cannot be
used for a second time and the latter is considered less
effective.1 Tenecteplase, a highly speciﬁc ﬁbrinolytic, can be a
reasonable alternative, especially for recurrent cases.§ Read the Editorial to this manuscript: Thrombotic obstruction in l
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A 25-year-old lady had been previously diagnosed as rheu-
matic mitral stenosis and had undergone repeated balloon
valvotomies in 2005, 2010 and 2012. For a calciﬁc restenosis,
she underwent mitral valve replacement with a Medtronic ATS
bileaﬂet metallic valve in November 2013. She was discharged
on Warfarin and Aspirin at an INR of 2.8. Three months later, in
February 2014, she was afﬂicted with PVT. Her transthoracic
echocardiographic examination (TTE) revealed a thrombotic
fused medial mitral prosthetic leaﬂet, with peak and meaneft-side prosthetic valves: Role of thrombolytic therapy.
 B.V. All rights reserved.
Fig. 2 – Post-thrombolysis transthoracic Doppler
echocardiogram across mitral valve showing significant
reduction of gradients. (Peak and mean gradients of 20 and
8 mm Hg respectively.)
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pulmonary artery pressure of 150 mm Hg. Her INR was 1.3.
Since she could not afford the cost of surgery, she was
thrombolysed with streptokinase at a dose of 0.5 million units
(MU) bolus and an infusion of 1.5 MU over 12 h. As ﬂuoroscopy
after 24 h revealed no beneﬁt, the infusion was extended for
another 24 h. Once this failed, an infusion of urokinase at a
dose of 4400 U/kg was started and continued for 48 h, further
extended to 72 h. Repeat ﬂuoroscopy still showed an immobile
leaﬂet. Patient, fortunately, had got stabilized with diuretics
and supportive medical care. She was given IV unfractionated
heparin round the clock and ﬂuoroscopy was checked on
alternate days. It was preferred over serial echocardiograms
due to cost constraints. After 15 days, bileaﬂet mobility was
noticed. She was then discharged on a higher dose of
Acenocoumarol with target INR 3–3.5, with Aspirin 150 mg.
But she was lost to follow-up.
A year later, in February 2015, she was admitted again with
complaints of acute onset breathlessness at rest for 5 days and
her INR was 1.33 on arrival. TTE revealed a recurrence of PVT,
with peak and mean gradients of 50 mm Hg and 30 mm Hg
respectively, and systolic pulmonary artery pressure of
140 mm Hg. The ﬁnding of an immobile leaﬂet was conﬁrmed
on ﬂuoroscopy. She could not afford the cost of surgery and
needed to be thrombolysed. Streptokinase could not be used
for the second time. Alteplase, another ﬁrst line drug was not
available in hospital pharmacy and waiting for it to be
indented would have resulted in signiﬁcant delay in therapy.
After discussion with patient and her relatives and after taking
her written informed consent, she was injected with an
intravenous bolus of 40 mg of Tenecteplase (1 mg/kg). A TTE
repeated in the evening after 4 h revealed adequate bileaﬂet
movement and peak and mean gradients had dropped to
20 and 8 mm Hg respectively. Her breathlessness was relieved
within 2 h of the injection. She was subsequently discharged in
a stable condition and is now under a close and strict follow-up
(Figs. 1 and 2).Fig. 1 – Pre-thrombolysis transthoracic Doppler
echocardiogram across mitral valve showing elevated
gradients. (Peak and mean gradients of 50 and 32 mm Hg
respectively.)3. Discussion
Valve thrombosis occur at an incidence of 1–2% per year in
mechanical valves and 0.7% per year in bioprosthetic valves.1
The most common cause is an inadequate anticoagulant
therapy as in our case. Although surgical treatment is
recommended for patients presenting in NYHA class III–IV
symptoms, ﬁbrinolysis as a preferred option is endorsed by
others.2 The ﬁbrinolytic agents used for treatment of prosthetic
valve thrombosis are streptokinase, urokinase, and recombi-
nant tissue plasminogen activator (alteplase). Streptokinase
and alteplase in various dosing regimes were studied in 220
episodes of PVT in the TROIA trial. The success rate was similar
for various doses of both drugs, however, the safety of low dose
and slow infusion of alteplase was signiﬁcantly higher
compared to other regimes.3 The newer ﬁbrinolytic agent
Tenecteplase is a synthetically engineered variant of alteplase,
with ease of administration as a single intravenous bolus dose.
It has been used extensively in acute myocardial infarction but
there are only a few anecdotal reports of its use in treatment of
mitral and aortic PVT. The largest data from India on
Tenecteplase use for PVT was published by Sharma et al.,4
who shared their experience of treating ten patients with left-
sided PVT using Tenecteplase and all of them responded
favorably. But none of these therapies was for a recurrence of
valve thrombosis. The use of Tenecteplase for recurrence of PVT
was reported by Hariram et al.5 They described the successful
use of Tenecteplase in thrombolysing a second episode of PVT in
an elderly woman in whom streptokinase was effective earlier.
In our case, the key additive feature is that the patient who had
failed to respond to extended dosing regimens of streptokinase
and urokinase in her earlier episode of valve thrombosis,
responded remarkably to a single bolus dose of Tenecteplase.
The increased ﬁbrin speciﬁcity, increased resistance to plas-
minogen activator inhibitor-1 (PAI-1) and longer half life could
have conferred the increased efﬁcacy to Tenecteplase. We
believe alteplase could have produced a similar beneﬁt as
Tenecteplase in our case, however the relative non inferiority or
superiority can be conclusively determined only through a
randomized clinical trial of the two drugs in such a context.
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PVT can be successfully and more conveniently treated
with Tenecteplase. More experience of its use might establish
its role as a thrombolytic agent of choice in management
of PVT, especially in the cases with recurrence of this disease.
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